The application of antibody-based agents in cancer therapy based on their mechanisms of action
Authors:
- Kewen QianKQKewen Qian
- Guangyao LiGLGuangyao Li
- Shuyi ZhangSZShuyi Zhang
- Yitan ZouYZYitan Zou
- Hongru AiHAHongru Ai
- Xinya ZhengXZXinya Zheng
- Wenyan FuWFWenyan Fu
- Changhai LeiCLChanghai Lei
- Shi HuSHShi Hu
Open Access
- 1 September 2025
- journal article
- review article
- Published by KEAI Publishing in Fundamental Research
- Vol. 5 (5) , 2343-2360
Abstract
Monoclonal antibodies and antibody-based agents are undergoing remarkable development in cancer immunotherapy. Based on their structural components, these antibodies mediate the crosslinking of tumor cells and the immune system, enabling specific antigen targeting and broad immune responses. Novel engineering strategies are aimed at improving both specificity and affinity of antigen recognition and enhancing the recruitment and activation of immune cells. Antibody-based therapeutics have been expanded for use in combination with other immunotherapies such as cellular immunotherapy and therapeutic vaccines. In this review, we provide comprehensive updates on the ongoing clinical development and evolving practices in the field, with a specific emphasis on the intricate mechanisms of action.Keywords
Funding Information
- National Natural Science Foundation of China (82322055)
- National Natural Science Foundation of China (81903140)
- National Natural Science Foundation of China (92169115)
- National Natural Science Foundation of China (82272792)
- Shanghai Shuguang Program (17CG35)
- Shanghai Rising-Star Program (23QA1405800)
This publication has 219 references indexed in Scilit:
- Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutionsCancer Communications, 2022
- Antibody variable region engineering for improving cancer immunotherapyCancer Communications, 2022
- Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factorsAnnals of Hematology, 2018
- Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanomaCancer Immunology, Immunotherapy, 2018
- Tumor angiogenesis and vascular normalization: alternative therapeutic targetsAngiogenesis, 2017
- Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functionsCancer Immunology, Immunotherapy, 2017
- Stem cell property epithelial‐to‐mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild‐type tumor cellsJournal of Cellular Biochemistry, 2010
- Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breastCancer, 2010
- The strange case of TGN1412Cancer Immunology, Immunotherapy, 2006
- Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c42003